Media stories about Microbot Medical (NASDAQ:MBOT) have been trending somewhat negative this week, Accern Sentiment reports. The research group scores the sentiment of news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Microbot Medical earned a daily sentiment score of -0.10 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 46.6272649071383 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
NASDAQ MBOT traded down $0.25 during mid-day trading on Friday, reaching $5.77. 23,085 shares of the stock were exchanged, compared to its average volume of 31,075. Microbot Medical has a 1-year low of $5.76 and a 1-year high of $22.80.
Microbot Medical (NASDAQ:MBOT) last announced its earnings results on Tuesday, August 14th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.04). sell-side analysts anticipate that Microbot Medical will post -2.4 earnings per share for the current year.
Microbot Medical Company Profile
Microbot Medical Inc, a pre-clinical medical device company, researches, designs, and develops micro-robotics assisted medical technologies targeting the minimally invasive surgery space. The company, through its ViRob and TipCAT micro-robotic technologies, is developing two product candidates, including the Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; and a self-propelling, semi-disposable endoscope, which is used in colonoscopy procedures.
Featured Story: Do Tariffs Work?
Receive News & Ratings for Microbot Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbot Medical and related companies with MarketBeat.com's FREE daily email newsletter.